Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain

References

• Melnikova I. Pain market. Nat Rev Drug Discov. 2010;9:589–590.
   PubMed Web of Science ®Google Scholar
• Gershell L, Goater JJ. Making gains in pain. Nat Rev Drug Discov. 2006;5:889–890.
   PubMed Web of Science ®Google Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.
   PubMed Web of Science ®Google Scholar
• Salvo F, Fourrier-Reglat A, Bazin F, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89:855–866.
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010;19:745–751.
   PubMed Web of Science ®Google Scholar
• Altman R, Bosch B, Brune K, et al. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015;75:859–877.
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563–7568.
   PubMed Web of Science ®Google Scholar
• Borhade N, Pathan AR, Halder S, et al. NO-NSAIDs. Part 3: nitric oxide-releasing prodrugs of non-steroidal anti-inflammatory drugs. Chem Pharm Bull (Tokyo). 2012;60:465–481.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov. 2015;14:329–345.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay M, Kodela R, Duvalsaint PL, et al. Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO- and H2S-releasing hybrid. Pharmacol Res Perspect. 2016;4:e00224.
   PubMed Web of Science ®Google Scholar
• Kodela R, Chattopadhyay M, Velazquez-Martinez CA, et al. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol. 2015;98:564–572.
   PubMed Web of Science ®Google Scholar
• Kashfi K, Chattopadhyay M, Kodela R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 2015;6:287–296.
   PubMed Web of Science ®Google Scholar
• Alvaro-Gracia JM. Licofelone–clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford). 2004;43(Suppl 1):i21–5.
   PubMed Web of Science ®Google Scholar
• Ding C, Cicuttini F. Licofelone (Merckle). IDrugs. 2003;6:802–808.
   PubMed Web of Science ®Google Scholar
• Koeberle A, Werz O. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Biochem Pharmacol. 2015;98:1–15.
   PubMed Web of Science ®Google Scholar
• Arhancet GB, Walker DP, Metz S, et al. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorg Med Chem Lett. 2013;23:1114–1119.
   PubMed Web of Science ®Google Scholar
• Clark P, Rowland SE, Denis D, et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbe nzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther. 2008;325:425–434.
   PubMed Web of Science ®Google Scholar
• Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev. 2011;111:5821–5865.
   PubMed Web of Science ®Google Scholar
• Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res. 2004;43:3–35.
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU. Prostanoids in nociception and pain. Biochem Pharmacol. 2007;73:165–174.
   PubMed Web of Science ®Google Scholar
• Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther. 2005;107:139–154.
   PubMed Web of Science ®Google Scholar
• Ji RR, Kohno T, Moore KA, et al. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705.
   PubMed Web of Science ®Google Scholar
• Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139:267–284.
   PubMed Web of Science ®Google Scholar
• Mizumura K, Sugiura T, Katanosaka K, et al. Excitation and sensitization of nociceptors by bradykinin: what do we know? Exp Brain Res. 2009;196:53–65.
   PubMed Web of Science ®Google Scholar
• Kawabata A. Prostaglandin E2 and pain–an update. Biol Pharm Bull. 2011;34:1170–1173.
   PubMed Web of Science ®Google Scholar
• Kuner R. Central mechanisms of pathological pain. Nat Med. 2010;16:1258–1266.
   PubMed Web of Science ®Google Scholar
• Nishihara I, Minami T, Watanabe Y, et al. Prostaglandin E2 stimulates glutamate release from synaptosomes of rat spinal cord. Neurosci Lett. 1995;196:57–60.
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Lorenzetti BB. Intrathecal administration of prostaglandin E2 causes sensitization of the primary afferent neuron via the spinal release of glutamate. Inflamm Res. 1996;45:499–502.
   PubMed Web of Science ®Google Scholar
• Myers LK, Kang AH, Postlethwaite AE, et al. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 2000;43:2687–2693.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang G, Grosser T. Prostanoids and inflammatory pain. Prostaglandins Other Lipid Mediat. 2013;104-105:58–66.
   PubMed Web of Science ®Google Scholar
• Guhring H, Gorig M, Ates M, et al. Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice. J Neurosci. 2000;20:6714–6720.
   PubMed Web of Science ®Google Scholar
• Scheuren N, Neupert W, Ionac M, et al. Peripheral noxious stimulation releases spinal PGE2 during the first phase in the formalin assay of the rat. Life Sci. 1997;60(PL):295–300.
   Google Scholar
• Schuh CD, Brenneis C, Zhang DD, et al. Prostacyclin regulates spinal nociceptive processing through cyclic adenosine monophosphate-induced translocation of glutamate receptors. Anesthesiology. 2014;120:447–458.
   PubMed Web of Science ®Google Scholar
• Schuh CD, Pierre S, Weigert A, et al. Prostacyclin mediates neuropathic pain through interleukin 1beta-expressing resident macrophages. Pain. 2014;155:545–555.
   PubMed Web of Science ®Google Scholar
• Kanda H, Kobayashi K, Yamanaka H, et al. COX-1-dependent prostaglandin D2 in microglia contributes to neuropathic pain via DP2 receptor in spinal neurons. Glia. 2013;61:943–956.
   PubMed Web of Science ®Google Scholar
• Eguchi N, Minami T, Shirafuji N, et al. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci U S A. 1999;96:726–730.
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82:85–94.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Patrono C. Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochim Biophys Acta. 2015;1851:422–432.
   PubMed Web of Science ®Google Scholar
• Masso Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62:1592–1601.
   PubMed Web of Science ®Google Scholar
• Pirlamarla P, Bond RM. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease. Trends Cardiovasc Med. 2016;16:30028–7.
   Google Scholar
• Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832–1847.
   PubMed Web of Science ®Google Scholar
• Graham DY, Opekun AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59.
   PubMed Web of Science ®Google Scholar
• Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19:1861–1876.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Force USPST. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:836–845.
   PubMed Web of Science ®Google Scholar
• Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119:706–714.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Araki H, Komoike Y, et al. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris. 2001;95:21–27.
   PubMed Web of Science ®Google Scholar
• Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. Faseb J. 2001;15:1622–1624.
   PubMed Web of Science ®Google Scholar
• Niederberger E, Tegeder I, Schafer C, et al. Opposite Effects of Rofecoxib on Nuclear Factor-kappaB and Activating Protein-1 Activation. J Pharmacol Exp Ther. 2003;304:1153–1160.
   PubMed Web of Science ®Google Scholar
• Niederberger E, Manderscheid C, Geisslinger G. Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochem Biophys Res Commun. 2006;342:940–948.
   PubMed Web of Science ®Google Scholar
• Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J. 2001;15:2742–2744.
   PubMed Web of Science ®Google Scholar
• Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98:736–747.
   PubMed Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12:1–278, iii.
   PubMed Web of Science ®Google Scholar
• Bhala N, Emberson J, Merhi A, et al.; Collaboration, C.a.t.N.T. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–779.
   PubMed Web of Science ®Google Scholar
• Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology. 2007;132:490–497.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528.
   PubMed Web of Science ®Google Scholar
• Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119:255–266.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama. 2000;284:1247–1255.
   PubMed Web of Science ®Google Scholar
• Peskar BM. Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing. Inflammopharmacology. 2005;13:15–26.
   PubMedGoogle Scholar
• Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 2012;18:2147–2160.
   PubMed Web of Science ®Google Scholar
• Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43:1262–1275.
   PubMed Web of Science ®Google Scholar
• Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2015;21:6817–6819.
   PubMed Web of Science ®Google Scholar
• Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14:809–15 e1.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
   PubMed Web of Science ®Google Scholar
• Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012;126:1955–1963.
   PubMed Web of Science ®Google Scholar
• White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension. 2007;49:408–418.
   PubMed Web of Science ®Google Scholar
• Oitate M, Hirota T, Koyama K, et al. Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats. Drug Metab Dispos. 2006;34:1417–1422.
   PubMed Web of Science ®Google Scholar
• Fok KC, Bell CJ, Read RB, et al. Lumiracoxib-induced cholestatic liver injury. Intern Med J. 2013;43:731–732.
   PubMed Web of Science ®Google Scholar
• Atukorala I, Hunter DJ. Valdecoxib: the rise and fall of a COX-2 inhibitor. Expert Opin Pharmacother. 2013;14:1077–1086.
   PubMed Web of Science ®Google Scholar
• Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687–696.
   PubMed Web of Science ®Google Scholar
• Argoff C, McCarberg B, Gudin J, et al. SoluMatrix ® diclofenac: sustained opioid-sparing effects in a phase 3 study in patients with postoperative pain. Pain Med. 2016;17:1933–1941.
   PubMed Web of Science ®Google Scholar
• Burnett BP, Levy RM. 5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity. Adv Ther. 2012;29:79–98.
   PubMed Web of Science ®Google Scholar
• Noguchi K, Okubo M. Leukotrienes in nociceptive pathway and neuropathic/inflammatory pain. Biol Pharm Bull. 2011;34:1163–1169.
   PubMed Web of Science ®Google Scholar
• Wallace JL. Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection. Inflamm Allergy Drug Targets. 2006;5:133–137.
   PubMedGoogle Scholar
• Gewirtz A. Lipoxin analogs: novel anti-inflammatory mediators. Curr Opin Investig Drugs. 2005;6:1112–1115.
   PubMedGoogle Scholar
• Lehmann C, Homann J, Ball AK, et al. Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein. Faseb J. 2015;29:5029–5043.
   PubMed Web of Science ®Google Scholar
• Ruiz J, Perez C, Pouplana R. QSAR study of dual cyclooxygenase and 5-lipoxygenase inhibitors 2,6-di-tert-butylphenol derivatives. Bioorg Med Chem. 2003;11:4207–4216.
   PubMed Web of Science ®Google Scholar
• Pillai AD, Rathod PD, Xavier FP, et al. Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design. Bioorg Med Chem. 2005;13:6685–6692.
   PubMed Web of Science ®Google Scholar
• Sharma RN, Xavier FP, Vasu KK, et al. Synthesis of 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents: an analogue-based drug design approach. J Enzyme Inhib Med Chem. 2009;24:890–897.
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep. 2008;10:43–48.
   PubMedGoogle Scholar
• Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI. Ann Rheum Dis. 2010;69:2118–2124.
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Raynauld JP, Caron J, et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis. 2010;69:2095–2101.
   PubMed Web of Science ®Google Scholar
• Bitto A, Squadrito F, Irrera N, et al. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions. Mediators Inflamm. 2014;(2014):790851.
   PubMedGoogle Scholar
• Levy R, Khokhlov A, Kopenkin S, et al. Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee- a subset analysis. Adv Ther. 2010;27:953–962.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Vuppalanchi R, Navarro V, et al. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med. 2012;156(857–60):W297–300.
   Google Scholar
• Davies NM, Roseth AG, Appleyard CB, et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther. 1997;11:69–79.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Del Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis. 2003;35(Suppl 2):S9–19.
   PubMedGoogle Scholar
• Fiorucci S, Distrutti E, Cirino G, et al. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology. 2006;131:259–271.
   PubMed Web of Science ®Google Scholar
• Van Goor H, Van Den Born JC, Hillebrands JL, et al. Hydrogen sulfide in hypertension. Curr Opin Nephrol Hypertens. 2016;25:107–113.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Hochberg MC, Marrero CE, et al. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Semin Arthritis Rheum. 2011;40:285–297.
   PubMed Web of Science ®Google Scholar
• Miglietta D, De Palma C, Sciorati C, et al. Naproxcinod shows significant advantages over naproxen in the mdx model of duchenne muscular dystrophy. Orphanet J Rare Dis. 2015;10:101.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Blackler RW, Chan MV, et al. Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid Redox Signal. 2015;22:398–410.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Caliendo G, Santagada V, et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010;159:1236–1246.
   PubMed Web of Science ®Google Scholar
• Blackler R, Syer S, Bolla M, et al. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One. 2012;7:e35196.
   PubMed Web of Science ®Google Scholar
• Distrutti E, Sediari L, Mencarelli A, et al. Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther. 2006;316:325–335.
   PubMed Web of Science ®Google Scholar
• Wallace JL. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci. 2007;28:501–505.
   PubMed Web of Science ®Google Scholar
• Cacciatore I, Marinelli L, Fornasari E, et al. Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer’s Disease. Int J Mol Sci. 2016;17:1035.
   PubMed Web of Science ®Google Scholar
• Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc). 2009;45:877–890.
   PubMed Web of Science ®Google Scholar
• Wong CC, Cheng KW, Papayannis I, et al. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology. Pharm Res. 2015;32:1663–1675.
   PubMed Web of Science ®Google Scholar
• Consalvi S, Biava M, Poce G. COX inhibitors: a patent review (2011-2014). Expert Opin Ther Pat. 2015;25:1357–1371.
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. 2007;59:207–224.
   PubMed Web of Science ®Google Scholar
• Hanke T, Rorsch F, Thieme TM, et al. Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1. Bioorg Med Chem. 2013;21:7874–7883.
   PubMed Web of Science ®Google Scholar
• Rorsch F, Buscato E, Deckmann K, et al. Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1). J Med Chem. 2012;55:3792–3803.
   PubMed Web of Science ®Google Scholar
• Rorsch F, Wobst I, Zettl H, et al. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. J Med Chem. 2010;53:911–915.
   PubMed Web of Science ®Google Scholar
• Xu D, Rowland SE, Clark P, et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 2008;326:754–763.
   PubMed Web of Science ®Google Scholar
• Brenneis C, Coste O, Schmidt R, et al. Consequences of altered eicosanoid patterns for nociceptive processing in mPGES-1-deficient mice. J Cell Mol Med. 2008;12:639–648.
   PubMed Web of Science ®Google Scholar
• Luz JG, Antonysamy S, Kuklish SL, et al. Crystal structures of mPGES-1 inhibitor complexes form a basis for the rational design of potent analgesic and anti-inflammatory therapeutics. J Med Chem. 2015;58:4727–4737.
   PubMed Web of Science ®Google Scholar
• Gupta A, Aparoy P. Insights into the structure activity relationship of mPGES-1 inhibitors: hints for better inhibitor design. Int J Biol Macromol. 2016;88:624–632.
   PubMed Web of Science ®Google Scholar
• Jin Y, Smith CL, Hu L, et al. Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib. Clin Pharmacol Ther. 2016;99:274–284.
   PubMed Web of Science ®Google Scholar
• St-Jacques B, Ma W. Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors. Exp Neurol. 2014;261:354–366.
   PubMed Web of Science ®Google Scholar
• Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015;1851:414–421.
   PubMed Web of Science ®Google Scholar
• Schiffmann S, Weigert A, Mannich J, et al. PGE2/EP4 signaling in peripheral immune cells promotes development of experimental autoimmune encephalomyelitis. Biochem Pharmacol. 2014;87:625–635.
   PubMed Web of Science ®Google Scholar
• Lin CR, Amaya F, Barrett L, et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther. 2006;319:1096–1103.
   PubMed Web of Science ®Google Scholar
• Flesch D, Merk D, Lamers C, et al. Novel prostaglandin receptor modulators–part II: EP receptor modulators; a patent review (2002-2012). Expert Opin Ther Pat. 2013;23:233–267.
   PubMed Web of Science ®Google Scholar
• Rausch-Derra L, Huebner M, Wofford J, et al. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in dogs with osteoarthritis. J Vet Intern Med. 2016;30:756–763.
   PubMed Web of Science ®Google Scholar
• Blanco MJ, Vetman T, Chandrasekhar S, et al. Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile. Bioorg Med Chem Lett. 2016;26:931–935.
   PubMed Web of Science ®Google Scholar
• Colucci J, Boyd M, Berthelette C, et al. Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]be nzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorg Med Chem Lett. 2010;20:3760–3763.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol. 2005;32:417–423.
   PubMed Web of Science ®Google Scholar
• Magrioti V, Kokotos G. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010–present). Expert Opin Ther Pat. 2013;23:333–344.
   PubMed Web of Science ®Google Scholar
• Hanke T, Merk D, Steinhilber D, et al. Small molecules with anti-inflammatory properties in clinical development. Pharmacol Ther. 2016;157:163–187.
   PubMed Web of Science ®Google Scholar
• Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11:81s–110s.
   PubMed Web of Science ®Google Scholar
• Patrono C, Rocca B. Nonsteroidal antiinflammatory drugs: past, present and future. Pharmacol Res. 2009;59:285–289.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Geisslinger G. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. Drug Discov Today. 2011;16:1001–1006.
   PubMed Web of Science ®Google Scholar
• Ramachandran SD, Schirmer K, Munst B, et al. In Vitro generation of functional liver organoid-like structures using adult human cells. PLoS One. 2015;10:e0139345.
   PubMed Web of Science ®Google Scholar
• Groeber F, Engelhardt L, Lange J, et al. A first vascularized skin equivalent for as an alternative to animal experimentation. Altex. 2016;22:4:415–422.
   Google Scholar
• Marx U, Walles H, Hoffmann S, et al. ‘Human-on-a-chip’ developments: a translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim. 2012;40:235–257.
   PubMed Web of Science ®Google Scholar
• Maubach KA, Davis RJ, Clark DE, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156:316–327.
   PubMed Web of Science ®Google Scholar